Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Am J Prev Med. 2023 Mar 11;65(1):92–100. doi: 10.1016/j.amepre.2023.02.005

Table 3.

Adjusted Relative Risk (95% CI) Of Receiving Cancer Screening Test During 4-Year Study Period.

Risk Factora,b Colonoscopy
and/or
Sigmoidoscopy
(N=2131)
FOBT (N=2131) Mammography
(N=1156)
Cervical
Cytology
(N=5068)
Model Including Regular Medical Provider c
Social Risk Group (Group 1 least risks)
  Group 2 0.82 (0.67,1.01) 1.04 (0.75,1.44) 0.93 (0.83,1.05) 1.02 (0.96,1.07)
  Group 3 0.92 (0.78,1.07) 1.24 (0.96,1.61) 0.98 (0.89,1.07) 1.00 (0.94,1.07)
  Group 4 (most risks) 0.70 (0.54,0.92) 1.52 (1.09,2.12) 0.94 (0.80,1.11) 0.90 (0.81,1.00)
Model Excluding Regular Medical Provider d
Social Risk Group (Group 1 least risks)
  Group 2 0.81 (0.65,0.99) 1.03 (0.74,1.43) 0.92 (0.81,1.03) 1.01 (0.95,1.07)
  Group 3 0.90 (0.77,1.06) 1.24 (0.96,1.6) 0.97 (0.88,1.06) 0.99 (0.93,1.06)
  Group 4 (most risks) 0.65 (0.50,0.86) 1.46 (1.05,2.04) 0.91 (0.77,1.07) 0.89 (0.80,0.99)
a

Reference group is in parenthesis.

b

Boldface indicates statistical significance (p < 0.05) between social risk group and receipt of cancer screening test.

c

Log-binomial model adjusted for age, sex, morbidity burden, having a regular medical provider, the length of Medicaid coverage, Area Deprivation Index quartile and social risk group.

d

Log-binomial model adjusted for age, sex, morbidity burden, the length of Medicaid coverage, Area Deprivation Index quartile and social risk group.